Skip Label
Bestil materialer
Metalyse

Metalyse - Administration

Metalyse

Single IV bolus administration

Metalyse® 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Actilyse®2-3

Single IV bolus administration

  • Metalyse® 25 mg comes as one single vial of powder for reconstitution

  • The dosing for Metalyse® 25 mg is with 5 weight-based tiers:

Metalyse® 25 mg
Weight (kg)Corresponding volume of reconstituted solution (ml)Tenecteplase (Units)Tenecteplase (mg)
< 603300015
≥ 60 to < 703.5350017.5
≥ 70 to < 804400020
≥ 80 to <904.5450022.5
≥ 905500025
Watch Metalyse® 25 mg reconstitution video

Why is Metalyse® 25 mg quicker and easier to use compared to Actilyse®?

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Metalyse® (tenecteplase) to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.1,4

Administration

Footnotes

  • †
    Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a one-time decile-weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.
  • ‡
    10% bolus over 1 minute, the remainer infused over 60 minutes.6
  • §
    One time 5 second bolus.6
  • Actilyse (alteplase) indication: Fibrinolytic treatment of acute ischaemic stroke (within 4,5 hours of last know well and after exclusion of intracerebral haemorhage by suitable imaging technology)

References

  1. Metalyse® European Summary of Product Characteristics.

  2. Menon BK, et al. Lancet 2022; 400:161-169.

  3. Bivard A, et al. Lancet Neurol. 2022; 21:520-27.

  4. Actilyse® European Summary of Product Characteristics.

  5. Dancsecs K. A. et al. Am J Emerg Med. 2021; 47:90-94.

  6. Miller, SE and Warach, SJ. Neurotherapeutics 2023; 20:664–678.

  7. Zhu A, et al. Res Pract Thromb Haemost. 2022; 6:e12795.